Sparfloxacin
FDA-approved product (tablet, oral), marketed as Zagam.
- Registered studies
- 1
- Lab records
- 49
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Fluoroquinolones
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01MA09
Repurposing investigation
Sparfloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA85.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli99.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis88.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 5 of 5 lab records
- E. coli: measured active in 11 of 11 lab records
- K. pneumoniae: measured active in 31 of 31 lab records
- M. tuberculosis: measured active in 2 of 2 lab records
Show the 49 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sparfloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Dapiprazole HydrochlorideExisting use: Glaucoma, Mydriasis, Open-angle glaucoma44.0% AI-predicted activityagainst E. coliNo documented evidence found
- Anileridine PhosphateExisting use: Opioid anesthetics44.0% AI-predicted activityagainst E. coliNo documented evidence found
- RelugolixExisting use: Metastatic prostate cancer, Neoplasm, Prostate adenocarcinoma and 1 more43.9% AI-predicted activityagainst E. coli50+ registered studies
- ZuranoloneExisting use: Depressive disorder, Major depressive disorder, Postpartum depression43.8% AI-predicted activityagainst E. coli17 registered studies
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive43.8% AI-predicted activityagainst E. coli5 registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder43.7% AI-predicted activityagainst E. coli1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more43.7% AI-predicted activityagainst E. coli15 registered studies
- Asciminib HydrochlorideExisting use: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic myelogenous leukemia, Neoplasm43.7% AI-predicted activityagainst E. coliNo documented evidence found
- InavolisibExisting use: Breast cancer, Breast neoplasm43.7% AI-predicted activityagainst E. coli36 registered studies
- Landiolol HydrochlorideExisting use: Atrial fibrillation, Atrial flutter, Supraventricular tachycardia43.7% AI-predicted activityagainst E. coli6 registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more43.6% AI-predicted activityagainst E. coli26 registered studies
- Nefazodone HydrochlorideExisting use: Major depressive disorder43.6% AI-predicted activityagainst E. coli6 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Patients Response to Early Switch To Oral:Osteomyelitis Study
NCT02099240 · start 2014-03-06
Registered record
- Registry ID
- NCT02099240
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics; intravenous antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2014-03-06
- Completion
- 2018-11-07
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventionoral antibiotics; intravenous antibioticsPhaseEarly phase 1Registry statusTerminated